News

Knight Therapeutics Achieves Milestone with JORNAY PM Launch

Knight Therapeutics Achieves Milestone with JORNAY PM Launch

Knight Therapeutics Achieves Health Canada Approval for JORNAY PM

In an exciting development for ADHD treatment, Knight Therapeutics Inc. (TSX: GUD) has received Health Canada approval for JORNAY PM™, a pioneering extended-release formulation of methylphenidate. This stimulant medication is intended for children suffering from Attention-Deficit Hyperactivity Disorder (ADHD) between the ages of 6 and 12.

Innovative Treatment for ADHD

JORNAY PM™ stands out as the first evening-dosed methylphenidate product available in Canada. The innovative formulation comprises microbeads with a unique delayed-release layer that allows the active ingredient to begin working in the morning, thus aligning with the natural daily rhythm of patients. This design not only mitigates ADHD symptoms upon waking but also sustains symptom control throughout the day.

Expert Insight on ADHD Management

Dr. Doron Almagor, a psychiatrist specializing in ADHD, praised the arrival of JORNAY PM™, remarking on how its distinct delivery mechanism significantly enhances morning functioning, an area where traditional treatments often struggle. He believes this treatment option is vital in supporting families seeking effective ADHD management solutions.

Clinical Validation of JORNAY PM

The effectiveness of JORNAY PM™ is backed by two pivotal phase 3 clinical trials, which were multicenter, randomized, and double-blind in nature. Both trials achieved their primary and secondary goals, showcasing a meaningful improvement in ADHD symptom management, starting from awakening through the afternoon and evening.

Future Growth for Knight Therapeutics

Samira Sakhia, the President and CEO of Knight, expressed pride over this approval, highlighting its significance for the company’s Canadian operations. The launch of JORNAY PM™ is anticipated in the latter half of 2025, which marks a substantial step towards a diversified ADHD treatment portfolio that caters to a variety of patient needs.

A Strategic Distribution Partnership

In May, Knight Therapeutics secured an exclusive distribution agreement with Ironshore Pharmaceuticals & Development, Inc., a subsidiary now part of Collegium Pharmaceutical, Inc. This partnership will encompass the distribution of JORNAY PM™ across Canada and Latin America.

Understanding ADHD and the Market Landscape

ADHD is recognized as a chronic, often lifelong neurodevelopmental disorder that influences both children and adults. The estimated prevalence rates indicate that about 5-9% of children and adolescents, alongside 3-5% of adults, are affected by this condition. The disorder typically manifests through symptoms of inattention, hyperactivity, and impulsivity, which can drastically hinder daily functioning.

Current first-line treatments generally include long-acting formulations derived from methylphenidate or stimulant medications that differ in their delivery methods. Notably, the market for extended-release methylphenidate products in Canada reached $469 million, reflecting an 8.1% rise in prescriptions and a notable 16% compound annual growth rate over four years.

About Knight Therapeutics Inc.

Headquartered in Montreal, Knight Therapeutics Inc. is committed to acquiring, licensing, and commercializing pharmaceutical products specifically for the Canadian and Latin American markets. Their subsidiary operations, under brands such as United Medical and Biotoscana Farma, reflect a broader strategy aimed at enhancing patient care across diverse medical needs. For more insights on their initiatives, visit www.knighttx.com.

Frequently Asked Questions

What is JORNAY PM?

JORNAY PM is an evening-dosed formulation of methylphenidate designed to treat ADHD in children aged 6 to 12, allowing for effective management throughout the day.

Why is JORNAY PM unique?

It is the only evening-dosed methylphenidate product available in Canada, with a formulation designed to release medication starting in the morning.

What do the clinical trials indicate?

The clinical trials demonstrate significant improvements in ADHD symptom control from awakening through the day and into the evening.

When will JORNAY PM be available?

It is expected to launch in the Canadian market in the second half of 2025.

What is Knight Therapeutics' focus?

Knight Therapeutics specializes in acquiring and commercializing pharmaceutical products, primarily for Canadian and Latin American markets, focusing on innovative treatments like JORNAY PM.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 110

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 121

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 100

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 108

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading

Top 5 Most Recently Viewed Articles

McDonald's Earnings Anticipation: Insights from Analysts Ahead

Updated Category News Views 110

Anticipating McDonald's Q3 Earnings Report As the third quarter approaches, McDonald's Corporation (NYSE: MCD) is preparing to unveil its earnings report, sparking interest among investors and analysts alike. This significant event is anticipated to occur just before the opening bell, offering crucial insights into the company's financial health and market position. What...

Continue Reading
BC Platforms Unveils Game-Changing AI Technology for Researchers

Updated Category News Views 281

BC Platforms Introduces BC Catalyst for Precision Medicine BC Platforms has officially launched BC Catalyst, an innovative AI-native analytics product designed to enhance precision medicine. This breakthrough technology integrates genomic and real-world data, allowing for actionable insights throughout the entire drug lifecycle. With BC Catalyst, the company aims to...

Continue Reading
TestFly Expands QA Testing Services with Red Cerberus Deal

Updated Category News Views 300

TestFly Enhances Service Offerings Through Acquisition TestFly, a prominent provider of innovative quality assurance testing solutions for the video game and mobile gaming sectors, has undertaken a significant move by acquiring Red Cerberus. This acquisition is set to transform the landscape of video game quality assurance by integrating Red Cerberus' expertise and...

Continue Reading
Unveiling Insurance Industry Abuses: New Podcast Series Launch

Updated Category News Views 173

Consumer Watchdog Introduces Insightful Podcast Series Smoke & Mirrors Debuts Today, Investigating Insurance Underpayments and Consumer Resilience Today marks the launch of a groundbreaking podcast series from Consumer Watchdog, titled "Smoke & Mirrors: Investigating Home Insurance Abuses," aimed at shedding light on the troubling practices that major insurance firms...

Continue Reading
MongoDB’s Leadership Change: Opportunities for Investors Ahead

Updated Category News Views 171

Understanding the Leadership Shift at MongoDB Recently, MongoDB (NASDAQ: MDB) has been a significant topic of discussion in investing circles due to its remarkable stock performance. After the stock's impressive rise from $188.81 to about $358 per share, many are questioning the right strategy—should investors lock in their profits now or remain committed for the long...

Continue Reading